Outset Medical, Inc. Common Stock (OM)
Outset Medical, Inc. is a healthcare technology company that develops and commercializes innovative dialysis solutions. Its flagship product, the Tablo Hemodialysis System, aims to simplify the delivery of dialysis treatment by integrating multiple functions into a compact, user-friendly device, improving access and efficiency for dialysis clinics and patients.
Company News
Outset Medical, a medical technology company, announced that members of its management team will participate in the RBC Capital Markets Global Health Care conference on May 20, 2025. The company's Tablo Hemodialysis System, which is FDA-cleared for use from the hospital to the home, represents a significant technological advancement in the dialysis industry.
Outset Medical reported strong Q4 earnings, with revenue and adjusted EPS beating analyst estimates. The company saw improved gross margins and reduced operating expenses, signaling progress towards profitability. Outset remains optimistic about future growth, projecting revenue of $115-$125 million by 2025.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Oppenheimer analyst Brian Nagel upgraded the rating for NIKE, Inc. (NYSE:NKE) from Perform to Outperform, while raising the price target from $110 to $120. Nike shares gained 0.8% to close at $95.57 on Thursday. See how other analysts view this stock. Morgan Stanley analyst Carlos De Alba upgraded Alcoa Corporation (NYSE:AA) from Equal-Weight to Overweight and boosted the price target from $36.5 to $50. Alcoa shares ...Full story available on Benzinga.com
Outset Medical (OM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).